Document Type
Article Restricted
Publication Date
11-2015
Journal Title
The Lancet Oncology
Volume Number
16
Issue Number
15
First Page
1445
Last Page
1446
Abstract
Patient-reported outcomes, including quality of life and symptom reports, have contributed to cancer care and research in many ways, including improved prognostication of how long patients with cancer will live. In The Lancet Oncology, Fabio Efficace and colleagues provide some of the first evidence that patient-reported outcomes from patients with intermediate-2-risk and high-risk myelodysplastic syndromes—specifically their ratings of fatigue—are a powerful indicator for their length of survival.